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Abstract
HIV-1 circulates both as free virus and within immune cells, with the level of free virus being predictive of clinical course.
Both forms of HIV-1 cross the blood-brain barrier (BBB) and much progress has been made in understanding the
mechanisms by which infected immune cells cross the blood-brain barrier BBB. How HIV-1 as free virus crosses the BBB is
less clear as brain endothelial cells are CD4 and galactosylceramide negative. Here, we found that HIV-1 can use the
mannose-6 phosphate receptor (M6PR) to cross the BBB. Brain perfusion studies showed that HIV-1 crossed the BBB of all
brain regions consistent with the uniform distribution of M6PR. Ultrastructural studies showed HIV-1 crossed by a
transcytotic pathway consistent with transport by M6PR. An in vitro model of the BBB was used to show that transport of
HIV-1 was inhibited by mannose, mannan, and mannose-6 phosphate and that enzymatic removal of high mannose
oligosaccharide residues from HIV-1 reduced transport. Wheatgerm agglutinin and protamine sulfate, substances known to
greatly increase transcytosis of HIV-1 across the BBB in vivo, were shown to be active in the in vitro model and to act
through a mannose-dependent mechanism. Transport was also cAMP and calcium-dependent, the latter suggesting that
the cation-dependent member of the M6PR family mediates HIV-1 transport across the BBB. We conclude that M6PR is an
important receptor used by HIV-1 to cross the BBB.
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Introduction
Human immunodeficiency virus-1 [1] crosses the blood-brain
barrier (BBB) to infect the central nervous system (CNS). It crosses
the BBB both within infected immune cells and as free virus
[2,3,4]. How free HIV-1 crosses the BBB is unclear as the brain
endothelial cells that comprise the vascular BBB are both CD4
and galactosylceramide negative [5]. In vivo and in vitro studies
show that interactions between the HIV-1 viral coat glycoprotein
gp120 and unknown glycoproteins on the cell membranes of brain
endothelia interact to induce a type of vesicular transport termed
adsorptive transcytosis [4,6,7], a transport that is enhanced by
protamine sulfate, wheatgerm agglutinin, and heparan sulfate, all
of which likely act by binding to the unknown glycoproteins
[7,8,9].
Evidence suggests that high mannose type glycans are involved
in HIV-1 internalization. High mannose glycans are one type of
carbohydrate moiety found on gp120 [10]. By way of these
mannose residues, gp120 can bind to and be internalized by
macrophages through a CD4-independent, mannose-specific
endocytic receptor pathway [11]; this is consistent with the high
mannose sites being related to HIV-1 infectivity [12].
One such mannose binding receptor is the insulin-like growth
factor-II/mannose-6 phosphate receptor (M6PR). This multi-
ligand transporter uniquely binds phosphorylated mannose (M6P),
a feature it uses to identify and route lysosomal enzymes to the
lysosomal compartment. HIV-1 is also routed to lysosomes by an
unknown endocytic process that is independent of CD4 [13,14].
Mannose-6 phosphate can inhibit gp160 binding [15], suggesting
that gp160 binds to the M6PR; furthermore, microglial uptake of
HIV-1 involves M6PR [16]. The M6PR is involved in the
trafficking of at least one other virus: herpes varicella-zoster [17].
The M6PR has recently been shown to be an inducible transporter
at the BBB for lysosomal enzymes [18,19,20]. These various lines
of evidence led us to postulate that the M6PR could be involved in
the transport of HIV-1 across the BBB.
Methods
Radioactive labeling of HIV-1 and bovine albumin
The virus HIV-1 (MN) CL4/CEMX174 (T1) prepared and
rendered noninfective by aldrithiol-2 treatment as previously
described [21,22] was a kind gift of the National Cancer Institute,
NIH. In brief, HIV-1(MN) CL.4/CEMX174(T1) was prepared by
infecting CEMX174(T1) cells (obtained from Peter Cresswell at
the Howard Hughes Medical Center) using virus obtained from
the HIV-1(MN)/H9CL.4 cell line [23]. HIV-1(MN) CL.4/
CEMX174(T1) cell cultures were grown in suspension using
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5850 cm2 roller bottles. Cells were maintained in complete RPMI
1640 supplemented with 10% heat-inactivated fetal bovine serum,
100 U/ml penicillin, and 100 ug/ml streptomycin. Each roller
bottle contained 300 ml of culture and was incubated at 37uC
while rotating at 0.20 rpm on roller racks. Cultures were harvested
at 3 to 4 day intervals by decanting 20 ml from each roller bottle
and refeeding with 20 ml of fresh medium. Immediately after
harvesting, the material was filtered using a Prostack filtration
system (Millipore Corp) containing a 0.8 A membrane. The
filtrate was treated with a final concentration of 1mM aldrithiol-2
and stored overnight at 4uC while stirring. Virus from infected
cells was recovered by continuous flow ultracentrifugation using a
CF-32 Ti rotor (Beckman Instruments) containing a 280 ml
sucrose gradient (25–50%; RNAse free) in TNE buffer
(0.01MTris–HCl pH 7.40, 0.1MNaCl, and 1mMEDTA in Milli-
Q water). After centrifugation, the gradient was monitored for
absorbance at 280 nm and collected in 25 ml fractions. The
density of each fraction was determined with a refractometer
(Bausch and Lomb). Virus containing fractions were identified by
UV absorption and density. Peak fractions were pooled, diluted to
below 20% sucrose with TNE buffer, ultracentrifuged to a pellet,
and resuspended in TNE at 1000x relative to the starting cell
culture filtrate. Aliquots were stored in a liquid N2 vapor phase
freezer.
The virus was radioactively labeled by the chloramine-T
method, a method which preserves vial coat glycoprotein activity
[24,25]. Two mCi of
131I-Na (Perkin Elmer, Boston, MA), 10 ug
of chloramine-T (Sigma Chemical Co, St. Louis, MO), and 5.0 ug
of the virus were incubated together for 60 sec. The radioactively
labeled virus (I-HIV) was separated from free iodine on a column
of Sepharose 200-B (Sigma) and had a specific activity estimated to
be between 50–150 Ci/g. Bovine serum albumin (Sigma; 5 ug)
was labeled by the chloramine-T method with 0.5 mCi of
125I-Na
(Perkin Elmer) and purified on a G-10 column (I-Alb).
Brain uptake of I-HIV-1
Brain uptake of I-HIV was determined by the brain perfusion
method of Banks et al. [26]. Male CD-1 mice from our in-house
colony (VA St. Louis, MO) were anesthetized with an ip injection
of 0.2 ml urethane (40%). All animal studies were approved by the
IACUC at the John Cochran Veterans Affairs Medical Center in
St. Louis, MO and were conducted at that facility. I-HIV was
diluted to a concentration of 16(10
5) cpm/ml in Zlokovic’s buffer
(pH 7.4; 7.19 g/l NaCl, 0.3 g/l KCl, 0.28 g/l CaCl2, 2.1 g/l
NaHCO3, 0.16 g/l KH2PO4, 0.17 g/l anhydrous MgCl2, 0.99 g/
l D-glucose, and 10 g/l bovine serum albumin (BSA; which was
added on the day of perfusion). The thorax was opened, the heart
was exposed, the descending thoracic aorta was clamped, and both
jugular veins were severed. A 26-gauge butterfly needle was
inserted into the left ventricle of the heart, and the buffer
containing the I-HIV was infused at a rate of 2 ml/min for 2, 4, 6,
8, or 10 min (n=6/time point). At the end of the perfusion time,
20 ml of lactated Ringer’s solution was infused through the heart
cannula in less than one minute to wash out the vascular space of
the brain and any virus loosely adhering to the luminal surface of
the brain vasculature. Mice were then decapitated and the brain
was collected, dissected into 10 regions (frontal cortex, parietal
cortex, occipital cortex, striatum, hippocampus, hypothalamus,
thalamus, cerebellum, midbrain, pons-medulla) after the method
of Glowinski and Iversen [27], and each region weighed and
counted in a gamma counter for 3 min. The olfactory bulb was
also collected, weighed, and its level of radioactivity determined.
Whole brain values were determined by summing the weights and
radioactivity levels of the constituent 10 brain regions for that
brain without inclusion of olfactory bulb. The brain/perfusion
ratios (ml/g) for each region and for whole brain were calculated
by the following formula:
Brain/perfusion ratio = (cpm/g of brain)/(cpm/ml of perfu-
sion).
The pharmacokinetic parameters of unidirectional influx rate
(Ki, ml/g-min) and initial volume of distribution within brain (Vi,
ml/g) were determined by first plotting the brain/perfusion ratios
(ml/g) against time (min) for each brain region. The Ki was taken
as the slope and Vi as the Y-intercept for the linear portion of the
brain/perfusion ratio vs time relation. The Ki and Vi with their
error terms were calculated by the least squares method with the
Prism 5.0 statistical package (GraphPad, Inc, San Diego, CA).
HIV-1 electron microscopy
Adult male CD-1 mice aged 8–10 weeks from our in house
colony (VA-St. Louis) received an injection into the jugular vein of
200 ul lactated Ringers solution containing 1% BSA with or
without 20 ug of HIV-1. The mice were decapitated 5 min after
the jugular injection, the brain sliced into 12 coronal sections, and
the 6th slice placed in 2.5% gluteraldehyde solution (2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.25
containing 3% sucrose and 2 mM calcium chloride). Slices were
submitted for EM with the EM evaluator blinded as to which mice
received HIV in their injections.
Tissue Processing for Standard Transmission Electron
Microscopy. The cerebral cortex from the 6
th slice was further
chopped in fixative with a razor and transferred to fresh fixative
for overnight fixation at 4uC. After washing in 0.1 M sodium
cacodylate buffer, pH 7.25 containing 5% sucrose, the tissue was
post-fixed in 1% osmium tetroxide in 0.1 M sodium cacodylate
buffer, pH 7.25 containing 2% sucrose overnight at 4uC. This was
followed, at room temperature, by a 2615 min wash in distilled
water, 1 h incubation in 2% aqueous uranyl acetate, dehydration
through graded ethanols to 100% ethanol, 2615 min in propylene
oxide and an overnight incubation in a 1:1 mixture of Polybed
resin and propylene oxide. The tissue was then incubated in fresh
Polybed resin (PolySciences) for 6 h, transferred to BEEM capsules
filled with fresh resin and polymerized overnight at 70uC. Thin
sections were cut on a Reichert Ultracut E ultramicrotome,
collected on 200 mesh copper grids, stained with uranyl acetate
and lead citrate, and viewed and photographed with a JEOL
100CX electron microscope.
Immuno-Gold Cytochemistry. Tissue processing and im-
muno-gold labeling was carried out as previously described
[28,29]. Tissue pieces from the 6
th anterior-posterior brain slice
were fixed with 4% paraformaldehyde and 1% glutaraldehyde in
PBS, pH 7.2, overnight at 4uC. The tissue was then washed with
PBS, dehydrated through graded ethanols to 100% ethanol and
infiltrated overnight in LR White resin (PolySciences), all at 4uC.
The tissue was then embedded in fresh LR White resin in BEEM
capsules and polymerized overnight at220uC by UV irradiation.
Thin sections were collected on formvar-coated nickel grids and
incubated on 20 ul drops of the following solutions in a closed
humidified container at room temperature unless noted otherwise:
PBS (161 min), 0.02M glycine (361 min), 1% bovine serum
albumen (BSA) and 1% fish gelatin in PBS (1610 min), 0.1% BSA
in PBS (161 min), goat anti-human HIV-1 gp120 (HIV-1SF2
gp120 antiserum from NIH aids reagents facility) or normal goat
serum (Sigma) diluted 1:10–1:100 in 0.1% BSA in PBS (overnight
at 4uC), 0.1% BSA in PBS (461 min), protein A-10 nm colloidal
gold diluted 1:100 in 0.1% BSA in PBS (1 hour), PBS (165 min),
2.5% glutaraldehyde in PBS (165 min), PBS (265 min) and
distilled water (265 min). After air drying the grids were post-
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photographed in a JEOL 100CX EM.
Primary culture of mouse brain microvascular endothelial
cells (BMECs)
BMECs were isolated by a modified method of Szabo ´ et al. [30]
and Nakagawa et al. [31]. In brief, the cerebral cortices from 8-
week-old CD-1 mice were cleaned of meninges and minced. The
homogenate was digested with collagenase type II (200 U/mL;
Invitrogen, Carlsbad, CA) and DNase I (30 U/mL; Sigma, St.
Louis, MO) in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen) containing 100 units/mL penicillin, 100 mg/mL
streptomycin, 50 mg/mL gentamicin and 2 mM GlutaMAX
TM-I
(Invitrogen) at 37uC for 40 min. Neurons and glial cells were
removed by centrifugation in 20% bovine serum albumin (BSA)-
DMEM (1,0006g for 20 min). The microvessels obtained in the
pellet were further digested with collagenase/dispase (1 mg/mL;
Roche, Mannheim, Germany) and DNase I (30 U/mL) in
DMEM at 37uC for 30 min. Microvessel endothelial cell clusters
were separated by 33% Percoll (Amersham Biosciences, Piscat-
away, NJ) gradient centrifugation (1,0006g for 10 min). The
obtained microvessel fragments were washed in DMEM (1,0006g
for 10 min) and seeded on 60 mm culture dishes (BD FAL-
CON
TM, BD Biosciences, Franklin Lakes, NJ) coated with
0.05 mg/mL fibronectin (Sigma), 0.05 mg/mL collagen I (Sigma)
and 0.1 mg/mL collagen IV (Sigma). They were incubated in
DMEM/Nutrient mixture F-12 HAM (DMEM/F-12) (Invitrogen)
supplemented with 20% plasma derived bovine serum (PDS,
Animal Technologies, Tyler, TX), 100 units/mL penicillin,
100 mg/mL streptomycin, 50 mg/mL gentamicin, 2 mM Gluta-
MAX
TM-I and 1 ng/mL basic fibroblast growth factor (bFGF;
Sigma) at 37uC with a humidified atmosphere of 5% CO2/95%
air. On the next day, the BMECs migrated from the isolated
capillaries and started to form a continuous monolayer. To
eliminate contaminating cells (mainly pericytes), BMECs were
treated with 4 mg/mL puromycin (Sigma) for the first 2 days
(Perrie `re et al., 2005). After 2 days of the treatment, puromycin
was removed from the culture medium. Culture medium was
changed every other day. After 7 days in culture, BMECs typically
reached 80–90% confluency.
Preparation of in vitro BBB models
BMECs (4610
4 cells/well) were seeded on the inside of the
fibronectin-collagen IV (0.1 and 0.5 mg/mL, respectively)-coated
polyester membrane (0.33 cm
2, 0.4 mm pore size) of a TranswellH-
Clear insert (Costar, Corning, NY) placed in the well of a 24-well
culture plate (Costar). Cells were cultured in DMEM/F-12
supplemented with 20% PDS, 100 units/mL penicillin, 100 mg/
mL streptomycin, 50 mg/mL gentamicin, 2 mM GlutaMAX
TM-I,
1 ng/mL bFGF and 500 nM hydrocortisone (Sigma) at 37uC with
a humidified atmosphere of 5% CO2/95% air until the BMEC
monolayers reached confluency (3 days). To check the integrity of
the BMEC monolayers, transendothelial electrical resistance was
measured before the experiments using an EVOM voltohmeter
equipped with STX-2 electrode (World Precision Instruments,
Sarasota, FL). The TEER of cell-free TranswellH-Clear inserts
were subtracted from the obtained values.
Endoglycosidase F1 treatment
Virus was treated with endoglycosidase F1 (eF1; CalbiochemH,
EMD Biosciences, La Jolla, CA) to cleave high mannose
oligosaccharides. HIV-1 (10 mg) was incubated for 24 hr at 37uC
in 50 mL of phosphate buffer (pH 5.5) containing 0.5 mM
phenylmethanesulfonyl fluoride (Sigma) and 2000 mU/mL eF1.
After the incubation period, sample was diluted with phosphate
buffer (pH 7.4). To remove eF1 (MW 32,000), the sample was
filtered by MicroconH YM-100 (Millipore, Bedford, MA) with the
100K cut-off membrane. The virus retained on the membrane was
used for radioactive labeling as described above. The iodinated
virus was purified by filtration on Sepharose 4B-200 (Sigma)
columns. Control HIV-1 was incubated in the same manner
without eF1.
Transendothelial transport of
131I-HIV-1
For the transport experiments, the medium was removed and
BMECs were washed with physiological buffer containing 1%
BSA (141 mM NaCl, 4.0 mM KCl, 2.8 mM CaCl2, 1.0 mM
MgSO4, 1.0 mM NaH2PO4, 10 mM HEPES, 10 mM D-glucose
and 1% BSA, pH 7.4). The physiological buffer containing 1%
BSA was added to the outside (abluminal chamber; 0.6 mL) of the
TranswellH insert. To initiate the influx of
131I-HIV-1 experi-
ments,
131I-HIV-1 (3610
6 cpm/mL) was loaded on the luminal
chamber. The side opposite to that to which
131I-HIV-1 was
loaded is the collecting chamber. Samples were removed from the
collecting chamber at 15, 30, 60 and 90 min and immediately
replaced with an equal volume of fresh 1% BSA/physiological
buffer. The sampling volume from the abluminal chamber was
0.5 mL. All samples were mixed with 30% trichloroacetic acid
(TCA; final concentration 15%) and centrifuged at 5,4006g for
15 min at 4uC. Radioactivity in the TCA precipitate was
determined in a gamma counter. The permeability coefficient
and clearance of TCA-precipitable
131I-HIV-1 were calculated
according to the method described by Dehouck et al. [32].
Clearance was expressed as microliters (uL) of radioactive tracer
diffusing from the luminal to abluminal (influx) chamber and was
calculated from the initial level of radioactivity in the loading
chamber and final level of radioactivity in the collecting chamber:
Clearance (uL) = [C]C 6 VC/[C]L, where [C]L is the initial
radioactivity in a uliter of loading chamber (in cpm/uL), [C]C is
the radioactivity in a uL of collecting chamber (in cpm/uL), and
VC is the volume of collecting chamber (in uL). During a 90-min
period of the experiment, the clearance volume increased linearly
with time. The volume cleared was plotted versus time, and the
slope was estimated by linear regression analysis. The slope of
clearance curves for the BMEC monolayer plus TranswellH
membrane was denoted by PSapp, where PS is the permeability 6
surface area product (in uL/min). The slope of the clearance curve
with a TranswellH membrane without BMECs was denoted by
PSmembrane. The real PS value for the BMEC monolayer [33] was
calculated from 1/PSapp =1/PSmembrane +1/PSe. The PSe values
were divided by the surface area of the TranswellH inserts
(0.33 cm
2) to generate the endothelial permeability coefficient (Pe,
in cm/min).
The effects of mannose, mannan, and mannose-6-phosphate,
(all purchased from Sigma) on
131I-HIV-1 transport were
determined by adding various concentrations of mannose (1–
50 mM), mannan (1–5 mg/mL), and mannose-6-phosphate (1–
10 mM) to the loading chamber with
131I-HIV-1. Effects of 8-
bromo-cAMP (0.1–1 mM, Sigma) and forskolin (1–30 mM,
Sigma) on
131I-HIV-1 transport was determined by pretreatment
of BMECs for 30 min prior to the transport experiment.
Uptake of
131I-HIV-1 by BMECs
The uptake of
131I-HIV-1 by BMECs was measured based on
the method for microvessels reported previously (Banks et al.,
2004) with a minor modification. BMECs were cultured in 24 well
culture plates for 3–4 days and washed three times with 1% BSA/
BBB and HIV
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BSA/physiological buffer containing
131I-HIV-1 (3610
5 cpm) and
125I-albumin (1610
6 cpm) for 15 min at 37uC. The incubation
supernatants were removed, and then cells were washed four times
with ice-cold physiological buffer. An acid wash technique was
used to remove the labeled virus binding to cell surface and to
evaluate the amounts of the labeled virus internalized into
BMECs. The cells were incubated with ice-cold acid wash buffer
(28 mM sodium acetate, 120 mM NaCl and 20 mM sodium
barbital, pH 3.0) for 6 min at 4uC. The buffer was removed and
the cells were subsequently washed again. Acid washed BMECs
were lysed with 150 mL of 1M NaOH. Aliquots (50 mL) of cell
lysate were measured cellular protein by BCA Protein Assay
Reagent (Pierce, Rockford, IL). To determine the TCA-precipi-
table radioactivity in the cell lysate (intracellular
131I-HIV-1) and
incubation buffer (surface-bound
131I-HIV-1), aliquots of cell
lysate (50 uL) and incubation buffer (100 microL) were mixed with
30% TCA (final concentration 10%) and centrifuged at 5,4006g
for 15 min at 4uC. Radioactivity in the TCA precipitate was
determined in a gamma counter. The uptake of TCA-precipitable
radiolabeled protein by BMECs was expressed as the cell/medium
ratio (radiolabeled protein amounts in the cells (in cpm/mg
protein)/radiolabeled protein concentration in the incubation
buffer (in cpm/uL)).
Various concentrations of mannose (1–30 mM), mannan (1–
5 mg/mL), mannose-6-phosphate (0.1–10 mM), N-acetyl-D-glu-
cosamine (GlcNAc, 0.1–50 mM) was incubated with
131I-HIV-1.
Effects of BAPTA (intracellular Ca
2+ chelator, 5–20 mM), A23187
(calcium ionophore, 1–10 mM), and verapamil (calcium channel
blocker, 20 uM) on
131I-HIV-1 uptake were determined by
pretreatment of BMECs for 30 min prior to the uptake
experiment. Wheat germ agglutinin (WGA, 1 mg/mL) and
protamine sulfate (1 mg/mL) were incubated with
131I-HIV-1
and
125I-albumin in the presence of various concentrations of
mannan (1–5 mg/mL). All test compounds were obtained from
Sigma.
Statistics
Statistical analysis was performed with the use of the Prism 5.0
program (GraphPad Software, Inc., San Diego, CA). Means are
shown with their standard error terms. Regression lines were
calculated by the least-squares method and are reported with their
correlation coefficient, r, n, and p values. Regression lines were
compared statistically with the Prism 5.0 program. One-way
analysis of variance (ANOVA) with Newman-Keuls multiple
comparison test and Dunnett’s multiple comparison test were
calculated by using Prism 5.0 Means are reported with their
standard error terms and n. Two means were compared by t test
analysis.
Results
Figure 1 (upper panel) shows the results for the uptake as
determined with the brain perfusion method. The Ki was 1.03 +/
2 0.42 ul/g-min and the Vi was 1.11 +/2 2.77 ul/g for whole
brain. The Ki for brain regions is shown in figure 1 (lower panel)
and ranged from 2.51 +/2 1.04 ul/g-min for hypothalamus to
0.44 +/20.19 ul/g-min for parietal cortex. ANOVA found no
statistical difference among the Ki values. The Vi ranged from
(21.19) +/2 6.71 ul/g for hypothalamus to 3.98 +/2 3.6 ul/g for
olfactory bulb (data not shown); ANOVA found no statistical
differences among the Vi values. This uniformity of uptake is
consistent with widespread distribution of binding sites at the BBB.
Ultrastructural examination revealed virus particles in the
capillaries and endothelial cells of the cerebral cortex (Figure 2,
panels A and B) and in the brain parenchyma (Figure 2, panel C)
5 min after its injection into the jugular vein, indicating that virus
had traversed the blood-brain barrier. HIV particles are 150 nm
in diameter and contain cone-shaped cores in tissue sections [34].
These observations were confirmed by immuno-gold localization
on thin sections of PFA-fixed but non-osmicated tissue embedded
in LR White using antibodies to HIV-1’s gp120 coat glycoprotein
and protein A-10 nm colloidal gold (Figure 2, panels D–H. The
abundance of labeled HIV particles decreased with distance from
capillaries as expected from the relatively short perfusion time in
these experiments. Virus is preferentially associated with the
myelin sheaths of myelinated nerves in the brain parenchyma
(Figure 2, panels G–H).
Uptake of I-HIV by BMEC during a 120 min study is shown in
panel A of figure 3 (n=4/time point). The results were fitted to a
one-site hyperbolic model with a Bmax of 135 +/2 9 ul/g and a
Kd of 19.1 +/2 4.0 min (r=0.935, n=20). The relation was
linear for the first 30 min (r=0.942, n=12, p,0.001) and
subsequent tests for BMEC uptake were done at 30 min.
Increasing concentrations of I-HIV resulted in a linear increase
in binding to the cell membranes (Figure 3, panel B) and a
decreasing cell/medium ratio (figure 3, panel C) consistent with I-
HIV-1 binding to a receptor site on BECs. The effects of
temperature on I-HIV (t=16.1, df=10, p,0.001) and I-Alb
(t=7.3, df=10, p,0.0001) on transport across the BMEC
monolayers are shown in figure 3 panels D and E, respectively
(n=6/group). Raw values at 37uC were (9.1 +/2 0.6)10
26 cm/
Figure 1. Uptake of HIV radioactively labeled with iodine (I-
HIV) by brain. Upper panel shows statistically significant relation
between brain/perfusion ratios and time for whole brain with a
unidirectional influx rate (Ki) of 1.03 +/2 0.42 ul/g-min. Lower panel
shows Ki for brain regions for which ANOVA showed no statistical
differences.
doi:10.1371/journal.pone.0039565.g001
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26 cm/sec for I-Alb and at 4uC
were (4.5 +/2 0.2)10
26 cm/sec for I-HIV and (4.6 +/2
1.0)10
26 cm/sec for I-Alb. Thus, in comparison to 37uC, at
4uC, transport of I-HIV was inhibited by about half and transport
of I-Alb was inhibited by about one-third.
Mannose and mannan, blockers of M6PR and other mannose
binding sites, were effective blockers of I-HIV uptake and
transport. Figure 4, panel A shows that mannose inhibited I-
HIV uptake [F(4,28)=4.39, p,0.01] and figure 4, panel C shows
that mannose inhibited I-HIV transport [F(4,40)=4.04, p,0.01].
Figure 4, panel B shows that mannan inhibited I-HIV uptake
Figure 2. Panels A and B: HIV particles (arrows) in the lumen (panel A) and in an endothelial cell (panel B) of blood vessels in mouse
cerebral cortex. The boxed regions show higher magnification images. Panel C: HIV (arrows) have traversed the endothelium of a blood vessel in
mouse brain cerebral cortex and gained access the perivascular space. Panels D–F: Colloidal gold labeled HIV in the lumen (arrowhead in panel E, and
panel F) and in endothelial cells (arrows in panels D and E) of mouse cerebral cortex capillaries. Panels G and H: HIV associated with myelin sheaths
(arrows) of nerve axons in mouse cerebral cortex. Thin sections were incubated with HIV-1SF2 gp120 antiserum diluted 1:100 and followed, after
washing, by incubation in protein A-10 nm gold diluted 1:100. B – brain parenchyma, E – endothelium, L – capillary lumen, RBC – red blood cell.
doi:10.1371/journal.pone.0039565.g002
Figure 3. Panel A shows kinetics of uptake of radioactively labeled HIV-1 (I-HIV) over time by BMEC. Panels B and C show linearity with
increases concentrations of I-HIV. Temperature decreased permeation of I-HIV (panel D) and of I-Albumin (panel E) in BMEC.
doi:10.1371/journal.pone.0039565.g003
BBB and HIV
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mannan inhibited I-HIV transport [F(3,23)=7.23, p,0.01].
These results show that a mannose binding site such as M6PR is
involved in HIV-1 transport across the BBB.
WGA and protamine sulfate greatly increase the permeation of
HIV-1 across the BBB and it is assumed that they potentiate the
endogenous mechanism by which HIV-1 crosses the BBB.
Mannan blocked both the WGA-induced and the protamine-
induced increases in I-HIV uptake. Figure 5, panel A shows the
results for WGA on I-HIV uptake: F(4,46)=30.8, p,0.001.
Tukey’s comparison test showed that WGA significantly increased
I-HIV uptake by 8 fold in comparison to control (p,0.01) and that
mannan at each concentration reduced I-HIV uptake in
comparison to the WGA only group (each comparison at
p,0.01). Neither WGA nor WGA + mannan had an effect on
I-Alb uptake (Figure 5, panel C). Figure 5, panel B shows the
results for protamine sulfate on I-HIV-1 uptake: F(4,38)=88.6,
p,0.01. Tukey’s comparison test showed that protamine in-
creased I-HIV uptake by over 13 fold in comparison to control
(p,0.01) and that mannan at each concentration reduced I-HIV
uptake in comparison to the protamine only group (each
comparison at p,0.01). Protamine also had an effect on I-Alb
uptake (Figure 5, panel D): F(4,38)=10.4, p,0.01. Tukey’s
comparison test showed that protamine increased I-Alb uptake by
almost 3 fold in comparison to control (p,0.01) and that mannan
at the 3 (p,0.05) and 5 (p,0.01) mg/ml concentrations reduced I-
Alb uptake in comparison to the protamine only group. For the
protamine experiments, the control value for I-HIV was 24.4 +/2
3.9 ul/mg-protein and for I-Alb was 3.3 +/2 0.7 ul/mg-protein
and the protamine-stimulated values were 310 +/2 48.9 ul/mg-
protein for I-HIV and 10 +/2 2.9 ul/mg-protein for I-Alb.
GlcNAc had no effect on I-HIV uptake. Overall, these results
show that the WGA and protamine sulfate enhanced permeation
of HIV-1 across the BBB is mediated through mannose binding
sites.
Figure 6 (panel A) shows that treating HIV-1 with endoglyco-
sidase F1, an enzyme which cleaves high mannose oligosaccha-
rides, reduced its transport by about 1/3 (t=7.08, df=18,
p,0.001). Neither permeation of the internal control I-Alb
(Figure 6, panel B) nor TEER (data not shown) were affected.
This shows that high mannose oligosaccharides are key to the
transport of HIV-1 across the BBB.
Whereas the above shows that mannose binding sites are
involved in HIV-1 transport, mannose-6-phosphate was used to
determine whether M6PR was specifically involved. Mannose-6-
phosphate inhibited both I-HIV uptake and transport. Uptake
(Figure 6, panel C) was inhibited as shown by ANOVA
[F(4,22)=17.3, p,0.001, n=3–6/group] and Dunnets showed
that concentrations of 1, 5, and 10 mM, but not 0.1 mM,
inhibited uptake (p,0.001). Transport (Figure 6, panel D) was
inhibited by as shown by ANOVA [F(3,38)=7.4, p,0.001, n=6–
12/group] and Dunnets showed that the concentration of 10 mM
(p,0.001), but not of 1 or 3 mM, inhibited transport. These
results show that M6PR was specifically involved in HIV-1
transport across the BBB.
We tested the importance of calcium on HIV-1 transport with a
calcium ionophore (A23187), a calcium chelator (BAPTA), and a
calcium channel blocker (verapamil). The intracellular calcium
chelator BAPTA affected cell uptake of I-HIV as shown in
Figure 7, panel A [F(3,35)=12.6, p,0.001; n=9/group].
Dunnett’s multiple comparison test showed that only 20 uM of
BAPTA produced a statistically significant effect (p,0.01) in
comparison to controls. BAPTA (10 uM) increased transport of I-
HIV across monolayers (Figure 7, panel B): t=3.06, df=10,
n=6/group, whereas verapamil (20 uM) was without effect.
BAPTA had no effect on TEER.
The calcium ionophore A23187 increased I-HIV transport
[F(3,29)=7.3, p,0.001, n=6–9/group] at the 10 uM dose
(p,0.001 by Dunnett’s); Figure 7, panel C. This compound also
decreased TEER [F(3,29)=41.6, p,0.001, n=6–9/group)] at
Figure 4. Uptake (panels A and B) and transport (panels C and D) were inhibited by mannose (panels A and C) and by mannan
(panels B and D).
doi:10.1371/journal.pone.0039565.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39565Figure 5. Mannan blocked the increase in I-HIV uptake induced by WGA (panel A) and by protamine (panel B) in BMEC cells. Neither
WGA nor WGA + mannan had an effect on I-Albumin uptake (panel C). Protamine increased uptake of I-Albumin by BMEC although much less
robustly than the uptake of I-HIV; mannan blocked this effect, although at higher doses than for the protamine/HIV-1 effect (panel D).
doi:10.1371/journal.pone.0039565.g005
Figure 6. Panel A: Cleavage of high mannose oligosaccharides from HIV with endoglycosidase F1 (eF1) reduced the transport of I-
HIV across BMEC. Panel B: The internal control of I-Albumin was unaffected. Mannose-6 phosphate, a ligand for and competitive inhibitor of the
mannose-6 phosphate receptor, inhibited the uptake (panel C) and permeation (panel D) of I-HIV across BMECs.
doi:10.1371/journal.pone.0039565.g006
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Figure 7, panel D.
We tested the importance of cAMP in HIV-1 transport by using
a cAMP analog (8-bromo-cAMP) and a adenylate cyclase activator
(forskolin). Figure 8, panel A shows that the cAMP analog 8-
bromo-cAMP partially inhibited I-HIV transport across BMEC:
F(3,21)=5.77, p,0.01 (n=5–6/group). TEER was increased at
the intermediate dose by 8-bromo-cAMP (Figure 8, panel B):
F(3,23)=2.84, p=0.06 (n=6/group). The adenylate cyclase
activator forskolin (Figure 8, panel C), also inhibited I-HIV
transport at its high dose: F(3,17)=3.41, p,0.05 (n=3–6/group).
Discussion
These studies show that HIV-1 uses the mannose-6 phosphate
receptor to cross the BBB as free virus. In brief, we used in vivo
pharmacokinetic methods, ultrastructural studies, and an in vitro
polarized monolayer model of the BBB in our studies.
We used as a basis for these studies key findings and models
previously used to study HIV-1 transport across the BBB. We used
a virus that was rendered non-infective by aldrithiol-2, a substance
that binds the zinc fingers of HIV-1 RNA. This treatment leaves
the viral coat unaltered and indeed was developed for use as a
vaccine [21,22]. Being non-infective conveys the advantage that
any virus we detect is known to be material which we injected into
the circulation; this is an important point as otherwise virus found
in brain could be assumed to have arisen from sites of infection
rather than immediately from blood. We previously showed that
the species barrier for HIV-1 does not extend to BBB penetration;
that is, HIV-1 is just as rapidly and efficiently taken up by mouse
brain endothelial cells as by human brain endothelial cells [35].
We first confirmed and extended previous in vivo studies
showing that free HIV-1 can cross the BBB of the mouse [4]. In
previous work, we used 4B-200 Sepharose chromatography to
demonstrate that radioactivity taken up by brain represents intact
virus and not viral coat proteins or degradation products [8]. Free
virus also crosses much faster than its surface coat protein gp120.
Here, we found that uptake of HIV-1 by the brain was rapid and
occurred throughout the CNS (Figure 1), consistent with the
widespread distribution of M6PR within the CNS [36]. Based on
specific activity of our I-HIV and published estimates of protein
molecules per virion, we roughly estimate that we infused 10
5–6
virions/ml [37]. This is well within the range of free virus
concentrations in patients with AIDS which typically is between
10
3 and 10
8 virions/ml [38,39]. The rate of 1 ul/g-min is as fast as
some small peptides that are transported by saturable systems and
about 500 times faster than the rate at which vascular markers
such as albumin leak into the brain.
Ultrastructural studies confirmed both the BBB penetration of
HIV-1 free virus and its rapid uptake (Figure 2). Five minutes after
iv injection of HIV-1, we found virus in the lumen, internalized in
brain endothelial cells, and in brain tissue. These results were seen
both with standard transmission electron microscopy and with
immuno-Gold staining. HIV-1 was located within the cytoplasm of
the brain endothelial cells rather than associated with intercellular
structures. This is consistent with HIV-1 crossing the BBB by the
transcytotic route, although passage by the paracellular route as
well was not ruled out. The dissociation of TEER and HIV-1
permeability in the dose-response curves for the calcium
ionophore A23187 (Figure 7) and the cAMP analog 8-bromo-
cAMP (Figure 8) also argues against HIV-1 crossing exclusively by
way of the paracellular route. However, calcium is also important
Figure 7. The intracellular calcium chelator BAPTA decreased cell retention of I-HIV at 20 uM (panel A) and increased transport rate
of I-HIV at 10 uM (panel B). This is consistent with an increased rate of transport across the BMEC. The calcium channel blocker verapamil had no
affect on transport. The calcium ionophore A23187 increased I-HIV permeability (panel C) and decreased TEER (panel D) in BMEC.
doi:10.1371/journal.pone.0039565.g007
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transport of HIV-1 was enhanced as well [40]. Immunogold
staining showed that HIV-like immunoactivity had a propensity
for myelinated neurons (Figure 2 G–H). Loss of myelin is a
hallmark of the HIV-1 infected brain and is thought to be
mediated through viral proteins, cytokines, neurotoxins, and
antibodies or enzymes directed against myelin [41,42,43]. The
association of HIV-1 with myelin so immediately after its crossing
reinforces these ideas and suggests that viral effects on myelin
could be direct and occur early.
We then used the in vitro monolayer model of the BBB to
further characterize and identify the transporter used by HIV-1 to
cross the BBB. We used primary cultures of mouse brain
microvascular endothelial cells (BMECs) grown as monolayers
on transwell inserts [44]. The in vivo BBB is polarized; that is, the
lipids, proteins, and transporters present on its luminal (blood side)
surface differ from those on its abluminal (brain side) surface. The
monolayer model used here polarizes after the fashion of the in
vivo BBB with the cell membrane facing into the buffer expressing
luminal properties and the cell membrane attached to the collagen
expressing abluminal properties. Thus, these monolayers are ideal
for studying BBB transport. Previous work has shown that
transport of HIV-1 across BMECs is a multi-stage process with
different properties for adherence, internalization, and transport
[8,45]. We, therefore, studied uptake (cell/medium ratios) and
permeation (permeability coefficients). Uptake involves adherence
and internalization of HIV-1 by brain endothelial cells, whereas
permeation reflects the complete transport of HIV-1 across the
brain endothelial cell from the donor (luminal) chamber into the
acceptor (abluminal) chamber. As expected, uptake was time
dependent and transport was temperature sensitive (Figure 3),
consistent with the vesicular- and energy-dependent processes
previously shown for HIV-1 transport across the BBB. At 37uC,
HIV-1 transport was 23% faster than that of I-Alb, despite the
much greater size of HIV-1. This demonstrates a selectivity to
HIV-1 transport across the monolayer as compared to I-Alb.
A series of experiments showed that HIV-1 transport was
dependent in part on binding to the mannose-6-phosphate
receptor (M6PR). Mannose, the mannose polymer mannan, and
mannose-6 phosphate each inhibited the uptake and transport of
HIV-1, demonstrating that transport was dependent on a mannose
binding site (Figure 4 and 6). WGA and protamine sulfate, agents
known to enhance the in vivo uptake of HIV-1 and gp120 [4,6,7],
were demonstrated here to enhance uptake of HIV-1 in our in
vitro model. It has been assumed that these substances are
enhancing the endogenous transport mechanism used by HIV-1 to
cross the BBB. Finding that these enhanced uptakes were blocked
by mannan was consistent with this assumption, demonstrating
that WGA and protamine sulfate act at least in part through a
mannose binding site (Figure 5). The importance of the mannose
binding site was further illustrated by treating HIV-1 with eF1, an
enzyme that cleaves high mannose oligosacharrides. This
decreased the ability of HIV-1 to cross the monolayer, demon-
strating the importance of these sugars in transport (Figure 6).
Finally, we showed that HIV-1 uptake and transport were
inhibited by mannose-6 phosphate, thus demonstrating the
mannose binding site was M6PR.
Overall, these studies show the importance of mannose binding
sites, especially the M6PR, in HIV-1 transport across brain
endothelial cells. They do not show that M6PR is exclusively used
Figure 8. The cyclic AMP analog 8-bromo-cAMP decreased transport of HIV-1 across BMEC (panel A) and at the 0.3 mM dose
increased TEER (panel B). The adenylate cylcase activator forskolin decreased transport of HIV-1 across BMEC (panel C).
doi:10.1371/journal.pone.0039565.g008
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transport is due to M6PR. They do show that M6PR is a major
transporter used by HIV-1.
Two versions of M6PR are known: a cation-dependent (CD-
M6PR) and a cation-independent (CI-M6PR) version [46]. The
work with the calcium chelator BAPTA and the calcium
ionophore A23187 shows an affect of calcium and so strongly
suggests that the CD-M6PR is involved in HIV-1 transport. The
smaller (46 kDa) CD-M6PR has one binding site for mannose-6-
phosphate and the larger (300 kDa) CI-M6PR has three binding
sites for mannose-6 phosphate, one of which also binds GlcNAc
[47]. We showed that GlcNAc had no effect on HIV-1 uptake,
suggesting that the CI-M6PR is not involved, although it may be
that GlcNAc binding does not sterically interfere with HIV-1
binding. The intracellular calcium chelator BAPTA decreased
uptake but increased transport of HIV-1 across the BMEC
monolayer (Figure 7). These seemingly contradictory findings can
be reconciled by the conclusion that BAPTA enhanced transit
time of HIV-1 across the monolayer. The calcium ionophore
A23187 had the opposite effect of calcium chelation in that it
enhanced HIV-1 transport; this could be a result of effects on tight
junctions or on transcytotic processes. Verapamil, a calcium
channel blocker, was without effect, suggesting that calcium
channels are not involved in HIV-1 transport. Overall, these
effects suggest that HIV-1 uses the calcium dependent M6PR to
cross the BBB.
Previous work has shown that cAMP inhibits the activity of
IGF-2, an action mediated through M6PR [48,49]. We postulated
that this down regulation could be evidence that cAMP induces
the internalization of the M6PR. If so, the cAMP would be
predicted to enhance HIV-1 transport. A role for cAMP in HIV-1
transport across the brain endothelial cell was shown in that both
the cAMP analog 8-bromo-cAMP and the cAMP activator
forskolin both enhanced transport (Figure 8). Thus, cAMP is an
important part of the intracellular machinery controlling HIV-1
transport across the BBB.
In conclusion, we showed with both pharmacokinetic and
ultrastructural studies that intravenous HIV-1 rapidly crosses the
BBB. We used an in vitro model of the BBB to show that the
mannose-6-phosphate receptor mediates this transport.
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